Avidity Biosciences initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...
Bank of America Securities Remains a Buy on Avidity Biosciences (RNA)
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Avidity Biosciences (RNA – Research ...
Avidity Biosciences (NASDAQ:RNA) Earns Sector Outperform Rating from Analysts at Scotiabank
Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...
Fintel on MSN4d
Scotiabank Initiates Coverage of Avidity Biosciences (RNA) with Sector Outperform Recommendation
Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Sector ...